Table 8.

Effects of 5-HT receptor activation on Shox2 in properties^{^a}

		Uninjured			SCI			Uninjured vs SCI
		mean ± SD	test	p	mean ± SD	test	p	test	p
5-HT₇ receptor activation	E_m, Δ from antagonist	3.6 ± 3	t₍₇₎ = 3.2	0.01^*	3.5 ± 4	t₍₁₁₎ = 2.9	0.01^*	t₍₁₈₎ = 0.02	0.9
	Rheobase current (% of antagonist)	87.0 ± 25	t₍₇₎ = 1.4	0.1	77.8 ± 20	t₍₁₂₎ = 3.9	0.001^*	t₍₁₉₎ = 0.9	0.3
	Firing frequency at 1.5× rheobase (% of antagonist)	119.2 ± 44	W = 9	0.4	101.1 ± 39	W = −5	0.9	U = 24	0.3
5-HT_2A receptor activation	E_m, Δ from antagonist	0.6 ± 3	W = −2	0.9	0.4 ± 2	t₍₉₎ = 0.5	0.6	U = 33	0.5
	Rheobase current (% of antagonist)	98.4 ± 29	t₍₇₎ = 0.1	0.8	91.4 ± 26	W = −14	0.2	U = 33.5	0.5
	Firing frequency at 1.5× rheobase (% of antagonist)	125.6 ± 57	W = −14	0.4	91.0 ± 24	t₍₉₎ = 1.1	0.2	U = 16.5	0.3
5-HT_2B/2C receptor activation	E_m, Δ from antagonist	−0.1 ± 1	t₍₆₎ = 0.2	0.8	3.1 ± 3	t₍₈₎ = 2.6	0.02^*	t₍₁₄₎ = 2.3	0.03^*
	Rheobase current (% of antagonist)	92.1 ± 19	t₍₆₎ = 1.0	0.3	73.2 ± 17	t₍₈₎ = 4.1	0.003^*	t₍₁₄₎ = 1.7	0.1
	Firing frequency at 1.5× rheobase (% of antagonist)	99.3 ± 9	W = −1	0.9	106.9 ± 22	t₍₇₎ = 0.8	0.4	U = 20	0.6

↵^aUninjured and SCI, one-sample t test or Wilcoxon signed rank test (W); Uninjured versus SCI, unpaired t test or Mann–Whitney U test.
↵*Statistical significance: p < 0.05.